UCB (OTCMKTS:UCBJF) Shares Gap Down – Here’s What Happened

Shares of UCB SA (OTCMKTS:UCBJF – Get Free Report) gapped down before the market opened on Friday . The stock had previously closed at $264.09, but opened at $248.40. UCB shares last traded at $248.40, with a volume of 1 shares traded.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on UCBJF shares. Jefferies Financial Group raised shares of UCB to a “hold” rating in a research note on Monday, August 3rd. Piper Sandler reissued a “neutral” rating on shares of UCB in a research report on Wednesday, July 22nd. Six equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy”.

Get UCB alerts:

Read Our Latest Stock Analysis on UCB

UCB Trading Down 0.1%

The business has a 50 day simple moving average of $275.26 and a 200-day simple moving average of $291.04. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33.

UCB Company Profile

(Get Free Report)

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.

Read More

• Five stocks we like better than UCB
• Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
• FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
• AST SpaceMobile Stock Soared 12%—This Was the Catalyst
• Snowflake’s AI Momentum Is Forcing a Fresh Look at the Stock

Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.